INSM Stock Analysis: Insmed | NASDAQ

Antibiotics, DPP1 Inhibitor, Prostacyclin, Gene Therapy

Total Rating 18

Safety 12

Buy Signal -0.81

Biotechnology
Industry Rotation: -20.0

Market Cap: 22.7B
Avg Turnover: 287M

Risk 3d forecast

Volatility53.4%

VaR 5^th Pctl8.42%

VaR vs Median-3.39%

Reward TTM

Sharpe Ratio-0.51

Rel. Str. IBD5.8

Rel. Str. Peer Group8.8

Character TTM

Beta0.264

Beta Downside0.657

Hurst Exponent0.410

Drawdowns 3y

Max DD56.54%

CAGR/Max DD1.06

CAGR/Mean DD3.90

EPS (Earnings per Share)

Last SUE: 0.59
Qual. Beats: 0

Revenue

Rev. CAGR: 54.03%
Rev. Trend: 90.2%

Last SUE: 3.61
Qual. Beats: 1

Warnings

Interest Coverage Ratio Critical

Beneish M-Score Likely Earnings Manipulation

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan -9.9% 9

Feb -0.1% 7

Mar -1.9% 29

Apr -3.8% 22

May -7.7% 21

Jun +3.4% 31

Jul -1.0% 5

Aug +2.6% 19

Sep +5.0% 10

Oct -6.8% 27

Nov +8.3% 45

Dec -3.8% 23

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: INSM Insmed

Insmed Incorporated is a U.S.-based biopharmaceutical company headquartered in Bridgewater, New Jersey, focused on developing and commercializing therapies for serious and rare diseases across the United States, Europe, Japan, and other international markets. The company markets ARIKAYCE, an approved inhaled antibacterial treatment for refractory nontuberculous mycobacterial (NTM) lung infections, and is evaluating it in a Phase 3 trial as part of a combination regimen for Mycobacterium avium complex (MAC) lung disease.

The companys pipeline is anchored by brensocatib, an oral DPP1 inhibitor currently in Phase 3 development for bronchiectasis and Phase 2 for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa, and treprostinil palmitil inhalation powder, which is in Phase 3 for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and Phase 2 for pulmonary arterial hypertension (PAH). Earlier-stage programs include INS1201, a microdystrophin AAV gene therapy for Duchenne muscular dystrophy in Phase 1, INS1148 (SCF248), a monoclonal antibody in Phase 2 for interstitial lung disease and asthma, and INS1202, an intrathecal gene therapy in Phase 1 for amyotrophic lateral sclerosis (ALS). Insmed also maintains pre-clinical research efforts in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Operating within the biotechnology sub-industry of healthcare, Insmed exemplifies a rare-disease biotech business model in which a single commercial product supports continued investment in a broad, multi-indication pipeline. Companies in this space typically depend heavily on R&D spending, pursue orphan drug designations to extend exclusivity and command premium pricing, and face binary clinical and regulatory outcomes that can significantly affect valuation.

Headlines to Watch Out For

Brensocatib Phase 3 bronchiectasis trial data readout
ARIKAYCE sales growth in refractory NTM lung infection market
Treprostinil palmitil Phase 3 results in PH-ILD

Piotroski VR-10 (Strict) 2.0

Net Income: -875.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.36 > 0.02 and ΔFCF/TA 0.77 > 1.0
NWC/Revenue: 105.1% < 20% (prev 444.6%; Δ -339.5% < -1%)
CFO/TA -0.37 > 3% & CFO -778.9m > Net Income -875.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.72 > 1.5 & < 3
Outstanding Shares: last quarter (217.4m) vs 12m ago 14.82% < -2%
Gross Margin: 83.27% > 18% (prev 75.72%; Δ 7.56% > 0.5%)
Asset Turnover: 49.65% > 50% (prev 16.05%; Δ 33.60% > 0%)
Interest Coverage Ratio: -9.72 > 6 (EBIT TTM -790.5m / Interest Expense TTM 81.3m)

Altman Z'' -7.01

A: 0.57 (Total Current Assets 1.63b - Total Current Liabilities 438.7m) / Total Assets 2.10b
B: -2.76 (Retained Earnings -5.81b / Total Assets 2.10b)
C: -0.35 (EBIT TTM -790.5m / Avg Total Assets 2.29b)
D: 0.56 (Book Value of Equity 757.5m / Total Liabilities 1.35b)
Altman-Z'' = -7.01 = D

Beneish M -1.24

DSRI: 1.37 (Receivables 215.3m/55.0m, Revenue 1.14b/398.1m)
GMI: 0.91 (GM 75.72% / 83.27%)
AQI: 1.40 (AQ_t 0.16 / AQ_t-1 0.11)
SGI: 2.86 (Revenue 1.14b / 398.1m)
TATA: -0.05 (NI -875.3m - CFO -778.9m) / TA 2.10b)
Beneish M = -1.24 (Cap -4..+1) = D

What is the price of INSM shares?

As of October 08, 2026, the stock is trading at USD 101.74 with a total of 3,161,414 shares traded. Over the past week, the price has changed by -10.86%, over one month by -18.54%, over three months by -9.84% and over the past year by -37.32%.

Current recommended Stop Loss: 94.50 (which is 7.1% or 1.3 ATR below the current price).

Is INSM a buy, sell or hold?

Insmed has received a consensus analysts rating of 4.79. Therefore, it is recommended to buy INSM.

StrongBuy: 19
Buy: 5
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the INSM price?

Analysts Target Price	197.7	94.4%

Insmed (INSM) - Fundamental Data Overview as of 07 October 2026

Market Cap USD = 22.7b (22.7b USD * 1.0 USD.USD)
P/E Forward = 97.0874
P/S = 19.9313
P/B = 34.8318
P/EG = 1.0916
Revenue TTM = 1.14b USD
EBIT TTM = -790.5m USD
EBITDA TTM = -770.0m USD
Long Term Debt = 543.5m USD (from longTermDebt, last quarter)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 616.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.4m
Net Debt = -544.1m USD (calculated: Debt 616.2m - CCE 1.16b)
Enterprise Value = 22.1b USD (22.7b + Debt 616.2m - CCE 1.16b)
Interest Coverage Ratio = -9.72 (Ebit TTM -790.5m / Interest Expense TTM 81.3m)
EV/FCF = -29.24x (Enterprise Value 22.1b / FCF TTM -756.7m)
FCF Yield = -3.42% (FCF TTM -756.7m / Enterprise Value 22.1b)
FCF Margin = -66.52% (FCF TTM -756.7m / Revenue TTM 1.14b)
Net Margin = -76.94% (Net Income TTM -875.3m / Revenue TTM 1.14b)
Gross Margin = 83.27% ((Revenue TTM 1.14b - Cost of Revenue TTM 190.3m) / Revenue TTM)
Gross Margin QoQ = 84.20% (prev 83.82%)
Tobins Q-Ratio = 10.53 (Enterprise Value 22.1b / Total Assets 2.10b)
Interest Expense / Debt = 13.20% (Interest Expense 81.3m / Debt 616.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -624.5m (EBIT -790.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.88 (Total Current Assets 1.63b / Total Current Liabilities 867.7m)
Debt / Equity = 0.81 (Debt 616.2m / totalStockholderEquity, last quarter 757.5m)
Debt / EBITDA = 0.71 (negative EBITDA) (Net Debt -544.1m / EBITDA -770.0m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -544.1m / FCF TTM -756.7m)
Total Stockholder Equity = 786.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.20% (Net Income -875.3m / Total Assets 2.10b)
RoE = -111.3% (Net Income TTM -875.3m / Total Stockholder Equity 786.7m)
RoCE = -59.42% (EBIT -790.5m / Capital Employed (Equity 786.7m + L.T.Debt 543.5m))
RoIC = -38.63% (negative operating profit) (NOPAT -624.5m / Invested Capital 1.62b)
WACC = 7.00% (E(22.7b)/V(23.3b) * Re(6.91%) + D(616.2m)/V(23.3b) * Rd(13.20%) * (1-Tc(0.21)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.37 | Cagr: 18.46%
[DCF] Fair Price = unknown (Cash Flow -756.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: 90.22 | Revenue CAGR: 54.03% | SUE: 3.61 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.36 | Chg30d=-1.02% | Revisions=+69% | Analysts=17
EPS current Year (2026-12-31): EPS=-1.54 | Chg30d=+0.63% | Revisions=+25% | GrowthEPS=+75.9% | GrowthRev=+198.2%
EPS next Year (2027-12-31): EPS=0.77 | Chg30d=-3.42% | Revisions=+12% | GrowthEPS=+150.2% | GrowthRev=+59.0%
[Analyst] Revisions Ratio: +59% (up=16, down=3)